A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
for
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma,
Location: Fairfax VA, Pittsburgh PA, Canton OH, Columbus OH,
Sponsor: OncoNano Medicine, Inc.
Sex: All
Age: 18+
Code: NCT06022029
Phase1, Recruiting
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
for
Hematologic Malignancy, Large B-cell Lymphoma,
Location: Los Angeles CA
Sponsor: Joshua Sasine, MD, PhD
Sex: All
Age: 18 - 70+
Code: NCT05887167
Phase1, Recruiting
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
for
Chronic Lymphocytic Leukemia (CLL),
Location: New Haven CT, Philadelphia PA, Bethesda MD, Durham NC,
Sponsor: Nurix Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT05131022
Phase1, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
for
Chronic Lymphocytic Leukemia,
Location: Rochester MN
Sponsor: Mayo Clinic
Sex: All
Age: 0+
Code: NCT06151730
Recruiting
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
for
Mantle Cell Lymphoma
Location: Duarte CA
Sponsor: City of Hope Medical Center
Sex: All
Age: 18+
Code: NCT06054776
Phase2, Recruiting
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
for
Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma,
Location: Atlanta GA
Sponsor: Emory University
Sex: All
Age: 18+
Code: NCT03501576
Recruiting
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
for
Mantle Cell Lymphoma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT06263491
Phase2, Recruiting
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Location: Boston MA, Tampa FL, Fort Wayne IN, St Louis MO,
Sponsor: BeOne Medicines
Sex: All
Age: 18+
Code: NCT06697184
Phase1, Phase2, Recruiting
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
Location: Baltimore MD, Charlottesville VA, Pittsburgh PA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT07003295
Phase2, Recruiting
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
for
Mantle Cell Lymphoma, Lymphoma
Location: Boston MA, New York NY, St Louis MO
Sponsor: Christine Ryan
Sex: All
Age: 18+
Code: NCT06854003
Phase2, Recruiting
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
for
Relapsed/Refractory Hematological Malignancies,
Location: East Brunswick NJ, Grand Rapids MI, Los Angeles CA
Sponsor: Ascentage Pharma Group Inc.
Sex: All
Age: 18+
Code: NCT07424833
Phase1, Recruiting
Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
for
Mantle Cell Lymphoma
Location: Toronto, Calgary, Vancouver
Sponsor: Canadian Cancer Trials Group
Sex: All
Age: 18+
Code: NCT07341191
Phase2, Recruiting
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
for
Non-Hodgkin Lymphoma Refractory/ Relapsed,
Location: New York NY, Buffalo NY, Nashville TN, St Louis MO,
Sponsor: LTZ Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT07121946
Phase1, Recruiting
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies